Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases

<table>Changes in the peak aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels following the switch from gefitinib to erlotinib treatment. The levels of both aminotransferases decreased after the change in EGFR-TKIs treatment.</table>

Lung Cancer International

fig1

Figure 1

Figure 1: Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases 